Anika Therapeutics, Inc., a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, recently announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is indicated for filling bone voids or defects of the skeletal system (i.e. extremities and pelvis), which are not intrinsic to the stability of the bone, created during surgery or resulting from traumatic injury.
iData ResearchAnika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment
These newly introduced products join Trabexus EB, which first received 510(k) clearance in 2015. TRABEXUS EB is a self-setting, gradually resorbable, calcium phosphate matrix enhanced with partially demineralized allograft particles.
iData ResearchVivorté Announces the Commercial Availability of FORTERA and REGENTO Bone Grafting Solutions for Orthopedic Surgery
By Payam Moghimi-Bidhendi and Jesse Spicer – iData Research Inc. The European orthopedic biomaterials market is broadly driven by the aging population and for being an attractive alternative for patients looking to avoid surgical implantation of permanent devices or hardware. Orthopedic surgeries are generally complicated, multi-stage procedures that result in longer recovery times and increased